This year, the Scleroderma Research Foundation (SRF) launched the CONQUER Registry, the first nationwide longitudinal scleroderma patient registry in the U.S.
What is the CONQUER Registry and why does it deserve our special consideration?
Scleroderma is heterogeneous; in other words, the disease presents in many different ways. This heterogeneity creates challenges for physicians in determining the best plan for treating any one patient.
The CONQUER Registry will collect long-term clinical data on thousands of patients over many years creating a platform for researchers to tease out subgroups of patients, and to study biological mechanisms and test therapies in more homogeneous groups of patients. In other words, the CONQUER Registry will be an important step toward more personalized medicine for scleroderma patients and improve our ability to conduct research studies and successful scleroderma clinical trials.
